{"id":68833,"date":"2023-04-16T14:27:12","date_gmt":"2023-04-16T14:27:12","guid":{"rendered":"https:\/\/www.pharmacie-vezere.com\/promotions\/?p=68833"},"modified":"2023-04-16T15:23:59","modified_gmt":"2023-04-16T15:23:59","slug":"lefficacite-et-la-securite-de-veklury-remdesivir-ont-ete-reaffirmees-chez-les-groupes-de-patients-presentant-un-risque-eleve","status":"publish","type":"post","link":"https:\/\/www.pharmacie-vezere.com\/promotions\/lefficacite-et-la-securite-de-veklury-remdesivir-ont-ete-reaffirmees-chez-les-groupes-de-patients-presentant-un-risque-eleve\/","title":{"rendered":"L’efficacit\u00e9 et la s\u00e9curit\u00e9 de Veklury\u00ae (Remdesivir) ont \u00e9t\u00e9 r\u00e9affirm\u00e9es chez les groupes de patients pr\u00e9sentant un risque \u00e9lev\u00e9."},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Gilead Sciences, Inc. (Nasdaq: GILD) a rapport\u00e9 des r\u00e9sultats positifs provenant de plusieurs \u00e9tudes li\u00e9es au COVID-19, qui seront pr\u00e9sent\u00e9s lors du 33\u00e8me Congr\u00e8s Europ\u00e9en de Microbiologie Clinique et des Maladies Infectieuses (ECCMID). Une \u00e9tude clinique de phase 3 a montr\u00e9 que Veklury\u00ae (remdesivir) \u00e9tait bien tol\u00e9r\u00e9 par les patients atteints d’une insuffisance r\u00e9nale mod\u00e9r\u00e9e \u00e0 s\u00e9v\u00e8re. De plus, une \u00e9tude r\u00e9trospective dans le monde r\u00e9el a indiqu\u00e9 que le traitement par Veklury\u00ae \u00e9tait associ\u00e9 \u00e0 un risque r\u00e9duit de d\u00e9c\u00e8s li\u00e9 au COVID-19 chez les patients atteints de cancer. Une autre analyse dans le monde r\u00e9el a montr\u00e9 que l’utilisation de Veklury\u00ae \u00e9tait associ\u00e9e \u00e0 un risque plus faible de r\u00e9admission \u00e0 l’h\u00f4pital chez les patients atteints de COVID-19 immunod\u00e9prim\u00e9s. En outre, une \u00e9tude de phase 1 examinant la s\u00e9curit\u00e9, la tol\u00e9rabilit\u00e9 et la pharmacocin\u00e9tique (PK) d’obeldesivir, anciennement connu sous le nom de GS-5245, un nouveau compos\u00e9 oral en cours de d\u00e9veloppement par Gilead pour le traitement de l’infection par le SARS-CoV-2, a d\u00e9montr\u00e9 qu’obeldesivir atteignait les concentrations plasmatiques th\u00e9rapeutiques attendues pour le traitement du COVID-19.<\/p>\n\n\n\n

\n

L’\u00e9tendue des donn\u00e9es cliniques et d’\u00e9vidence du monde r\u00e9el pr\u00e9sent\u00e9es \u00e0 ECCMID renforce davantage le profil d’efficacit\u00e9 et de s\u00e9curit\u00e9 solide de Veklury. Depuis le d\u00e9but de la pand\u00e9mie, Veklury a jou\u00e9 un r\u00f4le crucial dans le traitement des patients hospitalis\u00e9s atteints de COVID-19. Les donn\u00e9es du monde r\u00e9el d\u00e9montrent en outre son r\u00f4le dans la r\u00e9duction de la mortalit\u00e9 et des taux de r\u00e9admission \u00e0 l’h\u00f4pital dans les populations de patients vuln\u00e9rables, y compris les personnes vivant avec un cancer et d’autres conditions d’immunosuppression.<\/p>\nFrank Duff, MD, Vice-Pr\u00e9sident Senior, Responsable de la Th\u00e9rapeutique en Virologie chez Gilead Sciences.<\/cite><\/blockquote>\n\n\n\n

R\u00e9sultats de l’\u00e9tude<\/h2>\n\n\n\n

Une \u00e9tude de phase 3 (REDPINE) a \u00e9valu\u00e9 l’innocuit\u00e9 de Veklury chez des patients COVID-19 hospitalis\u00e9s pr\u00e9sentant une fonction r\u00e9nale r\u00e9duite. L’essai a inclus 243 participants adultes atteints de COVID-19 confirm\u00e9 et d’une insuffisance r\u00e9nale, dont 37% pr\u00e9sentaient une insuffisance r\u00e9nale aigu\u00eb (AKI), 26% une maladie r\u00e9nale chronique (CKD) et 37% une insuffisance r\u00e9nale en phase terminale (ESKD). Les participants ont \u00e9t\u00e9 randomis\u00e9s selon un ratio de 2:1 pour recevoir Veklury ou un placebo en plus des soins standard, avec 163 recevant Veklury et 80 recevant un placebo. Aucun nouveau signal de s\u00e9curit\u00e9 n’a \u00e9t\u00e9 identifi\u00e9 et aucune r\u00e9action ind\u00e9sirable suppl\u00e9mentaire n’a \u00e9t\u00e9 observ\u00e9e chez les 163 patients hospitalis\u00e9s pr\u00e9sentant une AKI, une CKD ou une ESKD et recevant Veklury pendant jusqu’\u00e0 5 jours.<\/p>\n\n\n\n

Dans la deuxi\u00e8me \u00e9tude, les patients immunod\u00e9prim\u00e9s trait\u00e9s avec Veklury avaient un risque r\u00e9duit de r\u00e9admission \u00e0 l’h\u00f4pital \u00e0 la fois \u00e0 30 et 60 jours. L’\u00e9tude a analys\u00e9 4 664 patients, dont 2 332 ont re\u00e7u un traitement avec Veklury et les autres ont servi de t\u00e9moins appari\u00e9s. Les r\u00e9sultats ont montr\u00e9 que pendant la vague Delta, les patients trait\u00e9s avec Veklury avaient un taux de r\u00e9admission \u00e0 60 jours inf\u00e9rieur de 16 % et pendant la vague Omicron, un taux inf\u00e9rieur de 13 %, par rapport aux t\u00e9moins appari\u00e9s. Ces r\u00e9sultats confirment davantage les preuves r\u00e9elles pr\u00e9sent\u00e9es lors de la CROI pr\u00e9c\u00e9dente, qui ont d\u00e9montr\u00e9 que l’utilisation de Veklury \u00e9tait associ\u00e9e \u00e0 un risque r\u00e9duit de r\u00e9admission toutes causes confondues \u00e0 30 jours.<\/p>\n","protected":false},"excerpt":{"rendered":"

Gilead Sciences, Inc. (Nasdaq: GILD) a rapport\u00e9 des r\u00e9sultats positifs provenant de plusieurs \u00e9tudes li\u00e9es au COVID-19, qui seront pr\u00e9sent\u00e9s lors du 33\u00e8me Congr\u00e8s Europ\u00e9en de Microbiologie Clinique et des Maladies Infectieuses (ECCMID). Une \u00e9tude clinique de phase 3 a montr\u00e9 que Veklury\u00ae (remdesivir) \u00e9tait bien tol\u00e9r\u00e9 par les patients atteints d’une insuffisance r\u00e9nale mod\u00e9r\u00e9e […]<\/p>\n","protected":false},"author":1,"featured_media":68840,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[684],"tags":[],"class_list":["post-68833","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles-pharmaceutiques"],"_links":{"self":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/68833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/comments?post=68833"}],"version-history":[{"count":6,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/68833\/revisions"}],"predecessor-version":[{"id":68841,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/68833\/revisions\/68841"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/media\/68840"}],"wp:attachment":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/media?parent=68833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/categories?post=68833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/tags?post=68833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}